Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study

Andreas A. Argyriou, Guido Cavaletti, Anna Antonacopoulou, Armando A. Genazzani, Chiara Briani, Jordi Bruna, Salvatore Terrazzino, Roser Velasco, Paola Alberti, Marta Campagnolo, Sara Lonardi, Diego Cortinovis, Marina Cazzaniga, Cristina Santos, Aikaterini Psaromyalou, Aikaterini Angelopoulou, Haralabos P. Kalofonos

Research output: Contribution to journalArticle

52 Citations (Scopus)

Abstract

BACKGROUND The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage-gated sodium channels (SCNAs) genes that might confer susceptibility to an increased incidence and severity of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients treated with either leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or oxaliplatin plus capecitabine (XELOX) for colorectal cancer (CRC). METHODS A total of 200 patients with CRC were genotyped with real-time polymerase chain reaction using locked nucleic acid hydrolysis probes or allele-specific primers. All patients had received oxaliplatin-based chemotherapy, either in the adjuvant or metastatic setting. The incidence and severity of cumulative OXAIPN was graded using the clinical version of the Total Neuropathy Score and the neurosensory National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of acute OXAIPN was assessed using a descriptive questionnaire (yes/no response format) at each clinical evaluation. Acute OXAIPN was present in 169 of 200 patients (84.5%), whereas after treatment discontinuation, the cumulative/chronic form of neurotoxicity occurred in 145 of 200 patients (72.5%). RESULTS In the logistic regression analysis adjusted for confounding factors, the overdominant model (CT vs CC + TT) of 2 single nucleotide polymorphisms (ie, SCN4A-rs2302237 and SCN10A-rs1263292) emerged as being significantly associated with an increased incidence of acute OXAIPN (rs2302237: odds ratio of 2.62 [95% confidence interval (95% CI), 1.15-6.00]; P =.019; and rs12632942: OR of 0.39 [95% CI, 0.17-0.88]; P =.023). However, only SCN4A-rs2302237 emerged as also being predictive of the clinical severity of acute OXAIPN (OR, 2.50 [95% CI, 1.35-4.63]; P =.0029) and the occurrence of cumulative/chronic OXAIPN (OR, 2.47 [95% CI, 1.04-5.85]; P =.037). CONCLUSIONS The results of the current study provide evidence to support a causal relationship between SCNA polymorphisms and OXAIPN. However, further studies from independent groups are warranted to confirm these results. Cancer 2013;119:3570-3577. © 2013 American Cancer Society. To the authors' knowledge, no reliable genetic or molecular biomarkers have been identified to date to detect patients at high risk of developing oxaliplatin-induced peripheral neuropathy (OXAIPN). The results of the current study provide evidence to support a causal relationship between voltage-gated sodium channel (SCNA) polymorphisms and OXAIPN.

Original languageEnglish
Pages (from-to)3570-3577
Number of pages8
JournalCancer
Volume119
Issue number19
DOIs
Publication statusPublished - Oct 1 2013

Fingerprint

oxaliplatin
Voltage-Gated Sodium Channels
Multicenter Studies
Peripheral Nervous System Diseases
Prospective Studies
Confidence Intervals
Incidence
Single Nucleotide Polymorphism
Colorectal Neoplasms

Keywords

  • biomarkers
  • chemotherapy-induced peripheral neuropathy
  • genotyping
  • neurotoxicity
  • oxaliplatin
  • SCNA

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Argyriou, A. A., Cavaletti, G., Antonacopoulou, A., Genazzani, A. A., Briani, C., Bruna, J., ... Kalofonos, H. P. (2013). Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study. Cancer, 119(19), 3570-3577. https://doi.org/10.1002/cncr.28234

Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity : Results from a prospective multicenter study. / Argyriou, Andreas A.; Cavaletti, Guido; Antonacopoulou, Anna; Genazzani, Armando A.; Briani, Chiara; Bruna, Jordi; Terrazzino, Salvatore; Velasco, Roser; Alberti, Paola; Campagnolo, Marta; Lonardi, Sara; Cortinovis, Diego; Cazzaniga, Marina; Santos, Cristina; Psaromyalou, Aikaterini; Angelopoulou, Aikaterini; Kalofonos, Haralabos P.

In: Cancer, Vol. 119, No. 19, 01.10.2013, p. 3570-3577.

Research output: Contribution to journalArticle

Argyriou, AA, Cavaletti, G, Antonacopoulou, A, Genazzani, AA, Briani, C, Bruna, J, Terrazzino, S, Velasco, R, Alberti, P, Campagnolo, M, Lonardi, S, Cortinovis, D, Cazzaniga, M, Santos, C, Psaromyalou, A, Angelopoulou, A & Kalofonos, HP 2013, 'Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study', Cancer, vol. 119, no. 19, pp. 3570-3577. https://doi.org/10.1002/cncr.28234
Argyriou, Andreas A. ; Cavaletti, Guido ; Antonacopoulou, Anna ; Genazzani, Armando A. ; Briani, Chiara ; Bruna, Jordi ; Terrazzino, Salvatore ; Velasco, Roser ; Alberti, Paola ; Campagnolo, Marta ; Lonardi, Sara ; Cortinovis, Diego ; Cazzaniga, Marina ; Santos, Cristina ; Psaromyalou, Aikaterini ; Angelopoulou, Aikaterini ; Kalofonos, Haralabos P. / Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity : Results from a prospective multicenter study. In: Cancer. 2013 ; Vol. 119, No. 19. pp. 3570-3577.
@article{58ee1d4383aa4df2b0848cac2983dd09,
title = "Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity: Results from a prospective multicenter study",
abstract = "BACKGROUND The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage-gated sodium channels (SCNAs) genes that might confer susceptibility to an increased incidence and severity of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients treated with either leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or oxaliplatin plus capecitabine (XELOX) for colorectal cancer (CRC). METHODS A total of 200 patients with CRC were genotyped with real-time polymerase chain reaction using locked nucleic acid hydrolysis probes or allele-specific primers. All patients had received oxaliplatin-based chemotherapy, either in the adjuvant or metastatic setting. The incidence and severity of cumulative OXAIPN was graded using the clinical version of the Total Neuropathy Score and the neurosensory National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of acute OXAIPN was assessed using a descriptive questionnaire (yes/no response format) at each clinical evaluation. Acute OXAIPN was present in 169 of 200 patients (84.5{\%}), whereas after treatment discontinuation, the cumulative/chronic form of neurotoxicity occurred in 145 of 200 patients (72.5{\%}). RESULTS In the logistic regression analysis adjusted for confounding factors, the overdominant model (CT vs CC + TT) of 2 single nucleotide polymorphisms (ie, SCN4A-rs2302237 and SCN10A-rs1263292) emerged as being significantly associated with an increased incidence of acute OXAIPN (rs2302237: odds ratio of 2.62 [95{\%} confidence interval (95{\%} CI), 1.15-6.00]; P =.019; and rs12632942: OR of 0.39 [95{\%} CI, 0.17-0.88]; P =.023). However, only SCN4A-rs2302237 emerged as also being predictive of the clinical severity of acute OXAIPN (OR, 2.50 [95{\%} CI, 1.35-4.63]; P =.0029) and the occurrence of cumulative/chronic OXAIPN (OR, 2.47 [95{\%} CI, 1.04-5.85]; P =.037). CONCLUSIONS The results of the current study provide evidence to support a causal relationship between SCNA polymorphisms and OXAIPN. However, further studies from independent groups are warranted to confirm these results. Cancer 2013;119:3570-3577. {\circledC} 2013 American Cancer Society. To the authors' knowledge, no reliable genetic or molecular biomarkers have been identified to date to detect patients at high risk of developing oxaliplatin-induced peripheral neuropathy (OXAIPN). The results of the current study provide evidence to support a causal relationship between voltage-gated sodium channel (SCNA) polymorphisms and OXAIPN.",
keywords = "biomarkers, chemotherapy-induced peripheral neuropathy, genotyping, neurotoxicity, oxaliplatin, SCNA",
author = "Argyriou, {Andreas A.} and Guido Cavaletti and Anna Antonacopoulou and Genazzani, {Armando A.} and Chiara Briani and Jordi Bruna and Salvatore Terrazzino and Roser Velasco and Paola Alberti and Marta Campagnolo and Sara Lonardi and Diego Cortinovis and Marina Cazzaniga and Cristina Santos and Aikaterini Psaromyalou and Aikaterini Angelopoulou and Kalofonos, {Haralabos P.}",
year = "2013",
month = "10",
day = "1",
doi = "10.1002/cncr.28234",
language = "English",
volume = "119",
pages = "3570--3577",
journal = "Cancer",
issn = "0008-543X",
publisher = "John Wiley and Sons Inc.",
number = "19",

}

TY - JOUR

T1 - Voltage-gated sodium channel polymorphisms play a pivotal role in the development of oxaliplatin-induced peripheral neurotoxicity

T2 - Results from a prospective multicenter study

AU - Argyriou, Andreas A.

AU - Cavaletti, Guido

AU - Antonacopoulou, Anna

AU - Genazzani, Armando A.

AU - Briani, Chiara

AU - Bruna, Jordi

AU - Terrazzino, Salvatore

AU - Velasco, Roser

AU - Alberti, Paola

AU - Campagnolo, Marta

AU - Lonardi, Sara

AU - Cortinovis, Diego

AU - Cazzaniga, Marina

AU - Santos, Cristina

AU - Psaromyalou, Aikaterini

AU - Angelopoulou, Aikaterini

AU - Kalofonos, Haralabos P.

PY - 2013/10/1

Y1 - 2013/10/1

N2 - BACKGROUND The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage-gated sodium channels (SCNAs) genes that might confer susceptibility to an increased incidence and severity of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients treated with either leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or oxaliplatin plus capecitabine (XELOX) for colorectal cancer (CRC). METHODS A total of 200 patients with CRC were genotyped with real-time polymerase chain reaction using locked nucleic acid hydrolysis probes or allele-specific primers. All patients had received oxaliplatin-based chemotherapy, either in the adjuvant or metastatic setting. The incidence and severity of cumulative OXAIPN was graded using the clinical version of the Total Neuropathy Score and the neurosensory National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of acute OXAIPN was assessed using a descriptive questionnaire (yes/no response format) at each clinical evaluation. Acute OXAIPN was present in 169 of 200 patients (84.5%), whereas after treatment discontinuation, the cumulative/chronic form of neurotoxicity occurred in 145 of 200 patients (72.5%). RESULTS In the logistic regression analysis adjusted for confounding factors, the overdominant model (CT vs CC + TT) of 2 single nucleotide polymorphisms (ie, SCN4A-rs2302237 and SCN10A-rs1263292) emerged as being significantly associated with an increased incidence of acute OXAIPN (rs2302237: odds ratio of 2.62 [95% confidence interval (95% CI), 1.15-6.00]; P =.019; and rs12632942: OR of 0.39 [95% CI, 0.17-0.88]; P =.023). However, only SCN4A-rs2302237 emerged as also being predictive of the clinical severity of acute OXAIPN (OR, 2.50 [95% CI, 1.35-4.63]; P =.0029) and the occurrence of cumulative/chronic OXAIPN (OR, 2.47 [95% CI, 1.04-5.85]; P =.037). CONCLUSIONS The results of the current study provide evidence to support a causal relationship between SCNA polymorphisms and OXAIPN. However, further studies from independent groups are warranted to confirm these results. Cancer 2013;119:3570-3577. © 2013 American Cancer Society. To the authors' knowledge, no reliable genetic or molecular biomarkers have been identified to date to detect patients at high risk of developing oxaliplatin-induced peripheral neuropathy (OXAIPN). The results of the current study provide evidence to support a causal relationship between voltage-gated sodium channel (SCNA) polymorphisms and OXAIPN.

AB - BACKGROUND The current prospective, multicenter study sought to identify single nucleotide polymorphisms of voltage-gated sodium channels (SCNAs) genes that might confer susceptibility to an increased incidence and severity of oxaliplatin-induced peripheral neuropathy (OXAIPN) in patients treated with either leucovorin, 5-fluorouracil, and oxaliplatin (FOLFOX) or oxaliplatin plus capecitabine (XELOX) for colorectal cancer (CRC). METHODS A total of 200 patients with CRC were genotyped with real-time polymerase chain reaction using locked nucleic acid hydrolysis probes or allele-specific primers. All patients had received oxaliplatin-based chemotherapy, either in the adjuvant or metastatic setting. The incidence and severity of cumulative OXAIPN was graded using the clinical version of the Total Neuropathy Score and the neurosensory National Cancer Institute Common Toxicity Criteria (version 3.0). The incidence of acute OXAIPN was assessed using a descriptive questionnaire (yes/no response format) at each clinical evaluation. Acute OXAIPN was present in 169 of 200 patients (84.5%), whereas after treatment discontinuation, the cumulative/chronic form of neurotoxicity occurred in 145 of 200 patients (72.5%). RESULTS In the logistic regression analysis adjusted for confounding factors, the overdominant model (CT vs CC + TT) of 2 single nucleotide polymorphisms (ie, SCN4A-rs2302237 and SCN10A-rs1263292) emerged as being significantly associated with an increased incidence of acute OXAIPN (rs2302237: odds ratio of 2.62 [95% confidence interval (95% CI), 1.15-6.00]; P =.019; and rs12632942: OR of 0.39 [95% CI, 0.17-0.88]; P =.023). However, only SCN4A-rs2302237 emerged as also being predictive of the clinical severity of acute OXAIPN (OR, 2.50 [95% CI, 1.35-4.63]; P =.0029) and the occurrence of cumulative/chronic OXAIPN (OR, 2.47 [95% CI, 1.04-5.85]; P =.037). CONCLUSIONS The results of the current study provide evidence to support a causal relationship between SCNA polymorphisms and OXAIPN. However, further studies from independent groups are warranted to confirm these results. Cancer 2013;119:3570-3577. © 2013 American Cancer Society. To the authors' knowledge, no reliable genetic or molecular biomarkers have been identified to date to detect patients at high risk of developing oxaliplatin-induced peripheral neuropathy (OXAIPN). The results of the current study provide evidence to support a causal relationship between voltage-gated sodium channel (SCNA) polymorphisms and OXAIPN.

KW - biomarkers

KW - chemotherapy-induced peripheral neuropathy

KW - genotyping

KW - neurotoxicity

KW - oxaliplatin

KW - SCNA

UR - http://www.scopus.com/inward/record.url?scp=84884902436&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84884902436&partnerID=8YFLogxK

U2 - 10.1002/cncr.28234

DO - 10.1002/cncr.28234

M3 - Article

C2 - 23821303

AN - SCOPUS:84884902436

VL - 119

SP - 3570

EP - 3577

JO - Cancer

JF - Cancer

SN - 0008-543X

IS - 19

ER -